Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ipatasertib Formulations in Healthy Subjects
NCT02063581Phase 1Completed
- Sponsor
- Genentech
- Start
- Feb 2014
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ipatasertib in solid tumor, breast cancer and prostate cancer (PCa) (2 arms), sponsored by Genentech. Primary endpoints: Area under the concentration time curve, Maximum concentration and 1 more. Started Feb 2014; status: completed.
02
Drugs
ipatasertib
03
Conditions
solid tumorbreast cancerprostate cancer (PCa)
Beyond the preview
Go deeper on NCT02063581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063581.